Track topics on Twitter Track topics that are important to you
Delegation of key Illinois business representatives gets insights on Vetter’s global production capabilities and US manufacturing status
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180417006205/en/
Taking a guided tour in one of Vetter’s aseptic production sites are Bruce Rauner (Governor of the State of Illinois, third from left), Sean McCarthy (Director at Illinois Department of Commerce and Economic Opportunity, first from left), Mark Peterson (President and CEO at Intersect Illinois, fourth from left) with Udo J. Vetter (Chairman of the company’s Advisory Board and member of the owner family, second from left) and the Vetter Managing Directors Peter Soelkner, Thomas Otto, Oliver Albrecht. Picture source: Vetter Pharma International GmbH
The governor was accompanied by a delegation of approximately twenty key state and county representatives including notable Illinois economic institutions and organizations. Together with Vetter management, the contingent discussed present local and global economic issues affecting manufacturing and trade. The delegation was also given a guided tour of one of the company’s aseptic production sites and its center for visual inspection and logistics.
“I enjoyed meeting members of the Vetter team and touring their high-quality pharmaceutical manufacturing facility here in the beautiful town of Ravensburg,” said Governor Rauner. “It was exciting to hear about their history and their growth plans for the future. Vetter is an important Illinois corporate citizen and we look forward to supporting their continued success in our state.”
“It is a distinct honor that the governor of Illinois paid a special visit to our German headquarters,” said Udo J. Vetter, Chairman of the company’s Advisory Board and member of the owner family. “This visit by such a prestigious delegation of individuals is another confirmation of the successful work and contribution we are making to the US life science industry.”
“Having the opportunity to discuss the current economic environment is of central importance for future initiatives,” added Peter Soelkner, one of the three Vetter Managing Directors involved in the gubernatorial meeting. “Also, the opportunity to better understand our individual positions and thoughts as trading partners from both sides of the Atlantic was most beneficial.”
Over the course of the visit, Vetter outlined the status of its site for injectable development services in Skokie. The current 37,000 sq ft facility at the Illinois Science+Technology Park is presently undergoing a further expansion of more than 12,000 sq ft which includes storage areas as well as office space. This expansion is due to the continuous increase in customer demand, and consequently, an increase in project work within the early clinical development of injectables.
In addition, Vetter reviewed its future plans for the company’s Des Plaines property. The pharmaceutical service provider completed the purchase of the 18-acre site in Des Plaines in 2017 as an integral part of the company’s ‘one stop shopping’ initiative, enabling a fast project start-up upon completion of cooperation agreements with customers. Initial renovations at the site are complete. Most recently, office space for Vetter’s US Key Account Management, Human Resources and Legal departments was equipped and is now ready for use.
Find the Vetter press kit, additional press releases, high-resolution pictures and more background information in our Download Center.
Headquartered in Ravensburg, Germany, Vetter is a global leading contract development and manufacturing organization (CDMO) with production facilities in Germany and the United States. The company, which currently employs 4,400 individuals worldwide, has long-term experience offering services ranging from early development support including clinical manufacturing, to commercial supply and various packaging solutions for vials, syringes and cartridges. Vetter’s customers range from small and midsize to the world’s top 20 pharmaceutical and biotech companies. As a leading solution provider, the CDMO recognizes its responsibility in supporting the needs of its customers in developing devices that contribute to increased patient safety, convenience, and enhanced compliance. In addition, the company places high importance on social responsibility including environmental protection and sustainability. Learn more about Vetter at www.vetter-pharma.com.
Vetter Pharma International GmbH
Corporate Spokesperson / Media Relations
Phone: +49 (0)751-3700-3729